Cardiology

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 118;

    In the January 2024 issue, the article “When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?” by Badwan OZ et al [Cleve Clin J Med 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034] contained an error in Figure 1.

  • In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Pooja Prasad, MD and Megha Prasad, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82-83; DOI: https://doi.org/10.3949/ccjm.91c.02002
  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82; DOI: https://doi.org/10.3949/ccjm.91c.02001
  • It’s a new year, looking back and looking forward
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 15-16; DOI: https://doi.org/10.3949/ccjm.91b.01024

    Reflections on highlights from 2023 and impending changes in 2024, along with some acknowledgments and farewells.

  • Conjunctival petechiae in infective endocarditis
    Akinori Sekizawa, MD, Ayaka Nagano, MD, Kenichi Hashimoto, MD, PhD and Yosuke Ono, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 20-21; DOI: https://doi.org/10.3949/ccjm.91a.23041

    A 75-year-old-man presented with a 33-day history of intermittent nocturnal fevers of 39°C (102°F) and truncal rashes. The rashes appeared on the same day as the fever.

  • Consumer-grade wearable cardiac monitors: What they do well, and what needs work
    Consumer-grade wearable cardiac monitors: What they do well, and what needs work
    Abdilahi Mohamoud, MBBS, Joseph Jensen, MD and Kevin G. Buda, DO
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 23-29; DOI: https://doi.org/10.3949/ccjm.91a.23030

    The authors review common consumer-grade wearables, including the accuracy of these monitors compared with medical-grade devices, and present an approach to managing rate or rhythm abnormalities identified on at-home monitoring.

  • Wearable cardiac monitors: Where do we stand?
    Jakub Sroubek, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 31-32; DOI: https://doi.org/10.3949/ccjm.91a.23081

    Wearable monitors perform well as screening tools for atrial fibrillation, but questions remain: Can they help with stroke prevention, what is their role in patients with known atrial fibrillation, and how do we streamline interpretation?

  • 2023 Update in ambulatory general internal medicine
    Jason T. Alexander, MD, Simran K. Singh, MD, Sachin D. Shah, MD, Brianna Lambert, MD and Jeremy P. Smith, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 40-46; DOI: https://doi.org/10.3949/ccjm.91a.23056

    Topics reviewed include prevention of chronic kidney disease progression, diet for preventing secondary cardiovascular disease, prevention of kidney-stone recurrence, drug therapy for weight loss, and cholesterol management.

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Osamah Z. Badwan, MD, Lorenzo Braghieri, MD, Warren Skoza, MD, Ankit Agrawal, MD, Venu Menon, MD and W. H. Wilson Tang, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 47-51; DOI: https://doi.org/10.3949/ccjm.91a.23034

    Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.

  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
    Abhayjit Singh, MD and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 53-63; DOI: https://doi.org/10.3949/ccjm.91a.23058

    Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease.

Pages